BMB-101 is a novel scaffold 5-HT2C Gq-protein biased agonist developed using structure-based drug design. It was explicitly designed for chronic treatment of neurological disorders where tolerance and drug resistance are common issues. Biased agonism at the 5-HT2C receptor is one of its key features and adds another layer of functional selectivity within a well-validated target. BMB-101 works exclusively via the Gq-protein signalling pathway and avoids beta-arrestin activation. That is crucial to minimize the risk of receptor desensitization and tolerance development. This provides a novel mechanism anti-epileptic drug designed to provide sustained seizure relief in hard-to-treat patient populations.